New drug shows promise in shrinking head and neck tumors before surgery
NCT ID NCT07094685
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether the drug ivonescimab, given before surgery, can shrink tumors in people with stage II-IV head and neck cancer that can be removed. Ivonescimab is a type of antibody that helps the immune system fight cancer. The study will enroll 28 adults whose tumors have a specific marker (PD-L1 CPS ≥ 1). The main goal is to see how many patients have a major reduction in tumor cells after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (a bispecific antibody that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could lead to a new treatment option that shrinks head and neck tumors before surgery, potentially improving long-term outcomes.
- What could go wrong
- This is an early phase II trial with only 28 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
- Promising new combo targets tough head and neck cancer
- AI-Designed mRNA vaccine takes on advanced tumors in first human test
- New drug cocktail targets Hard-to-Treat cancers
- New drug combo shows promise in shrinking head and neck tumors before surgery